Latest News and Press Releases

MALVERN, Pa., May 23, 2022 (GLOBE NEWSWIRE) -- Ocugen, Inc. (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene therapies, biologicals, and...

Participants receiving a booster dose six months after second dose of COVAXIN™ saw significant increase (>10-fold across Alpha, Beta, Delta and Delta Plus variants) in neutralizing titers compared...

Level of vaccine-induced spike and nucleoprotein antibodies titers demonstrated to be comparable to that following natural infectionImmune memory against conserved nucleoprotein may provide an added...

COVAXIN effectively neutralizes Brazil variant along with UK variant and India double mutant variantPotential effectiveness against multiple variants reduces the possibility of mutant virus...

Data from 25,800 participants in Phase 3 trial in India, received vaccine or placebo in a 1:1 ratio showed that the vaccine candidate was well tolerated and demonstrated 81% efficacy in preventing...

Companies will co-develop inactivated vaccine candidate, COVAXIN™, to prevent COVID-19 infection in the US Builds upon the promising safety and immunogenicity data in the Phase 1 and Phase 2...